查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085308

心臟生物標記診斷試劑盒市場：2026-2032年全球市場預測（按生物標記類型、適應症、檢測類型、購買方式、應用和最終用戶分類）

Cardiac Biomarker Diagnostic Kits Market by Biomarker Type, Indication, Testing Type, Purchasing Mode, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，心臟生物標記診斷試劑盒市場將成長至 57.1 億美元，複合年成長率為 7.47%。

主要市場統計數據
基準年 2025 34.5億美元
預計年份：2026年 36.9億美元
預測年份：2032年 57.1億美元
複合年成長率 (%) 7.47%

心臟生物標記診斷試劑盒在現代心血管醫學中發揮核心作用，它們能夠幫助臨床醫生快速檢測心肌損傷、對胸痛進行分診、監測心臟衰竭並支持及時有效的治療決策。高敏肌鈣蛋白I和T的檢測法仍是疑似急性心肌梗塞的臨床依據，而BNP和NT-proBNP則有助於評估心臟衰竭，CK-MB、肌紅蛋白、D-二聚體以及新興的發炎或缺血性生物標記等指標正在拓展診斷範圍。

全球疾病負擔持續加重，推動了這個市場的發展。根據世界衛生組織（世衛組織）估計，2019年全球有1,790萬人死於心血管疾病，佔全球死亡總數的32%，其中絕大多數死於心肌梗塞和中風。這個臨床現實凸顯了急診室、中心檢查室、門診和照護現場點對準確、快速且可擴展的心臟生物標記檢測的需求。

對於製造商、經銷商、實驗室和醫療保健系統而言，策略機會在於提供兼具分析靈敏度、工作流程效率、合規性和可靠獲取途徑的心臟生物標記診斷試劑盒。隨著臨床指引不斷強調快速的「陽性」和「陰性」檢測流程，能夠平衡檢測效能、操作速度和實證患者管理的醫療機構正日益獲得競爭優勢。

心臟生物標記檢測領域的變革性變化

心臟生物標記診斷試劑盒的格局正在從單一分析物、依賴檢查室的檢測轉向整合了高靈敏度檢測、照護現場平台、多重檢測和數位化決策支援的綜合診斷管道。在急診科，採用連續高靈敏度肌鈣蛋白檢測的快速診斷方案正在實施，以縮短診斷時間、改善患者就診流程，並在臨床適用的情況下減少不必要的住院。

人工智慧對心臟生物標記診斷的累積影響

人工智慧 (AI) 正在對心臟生物標記診斷試劑盒的整個價值鏈產生累積影響，從檢測方法開發和生產品管到臨床解讀和醫院工作流程最佳化。 AI 驅動的分析可以識別生物標記模式，將肌鈣蛋白檢測結果與心電圖觀察和患者病歷整合，並為胸痛或疑似心臟衰竭患者的風險分層模型提供支持。

全球心臟生物標記市場關鍵區域洞察

北美仍然是心臟生物標記診斷試劑盒的主要市場，這得益於急診科的高使用率、完善的檢查室基礎設施、先進的保險報銷機制以及高靈敏度肌鈣蛋白檢測的廣泛應用。在美國和加拿大，市場需求主要受冠狀動脈疾病和心臟衰竭持續高發生率以及醫療保健系統旨在改善胸痛分診和減少不必要住院治療的目標所驅動。

用於策略市場定位的關鍵群體特定洞察

在東協，隨著各國政府擴大醫院網路、投資全民健保體系，並尋求在都市區和二級醫療機構提供經濟高效的照護現場心臟檢測，該市場的重要性日益凸顯。在急救醫療體係正在發展、私人診斷連鎖機構正在擴大高敏肌鈣蛋白檢測和心臟衰竭生物標記檢測服務覆蓋範圍的地區，市場需求最為旺盛。

各國對心臟生物標記診斷試劑盒的重點了解

美國是心臟生物標記診斷試劑盒市場中最具商業性，這得益於其大規模的醫院網路、較高的心血管疾病盛行率、由美國食品藥物管理局 (FDA) 監管的成熟診斷流程，以及急診室對快速分流的強勁需求。在加拿大，省級醫療保健系統、以品質為導向的採購以及高靈敏度肌鈣蛋白檢測方案的日益普及，都帶來了穩定的需求。同時，隨著公共和私人醫療保健投資的增加以及診斷技術的現代化，墨西哥的檢測覆蓋範圍也在擴大。

業界領導者使用的實用建議

產業領導者應優先考慮高靈敏度肌鈣蛋白、NT-proBNP 以及可擴展的照護現場(PoC) 平台，以滿足實際臨床工作流程的需求。產品策略應分散式檢查和可涵蓋急診、急診診所、救護車、當地醫院和門診心臟衰竭計畫的分散式檢查室模式。

調查方法

本執行摘要基於系統性的研究途徑，結合了檢驗的二手資料、監管審查、臨床指南分析和市場三角驗證。主要參考文獻包括世界衛生組織 (WHO)、各國衛生組織、美國食品藥物管理局 (FDA) 和歐盟委員會等監管機構的數據，以及權威專業學會發布的心血管疾病指南。

結論

心血管疾病仍然是全球主要死因之一，醫療系統也在尋求更快、更可靠的診斷途徑，因此，心臟生物標記診斷試劑盒市場預計將繼續保持其重要的戰略地位。高靈敏度肌鈣蛋白檢測、心臟衰竭生物標記、照護現場以及數位化整合正在塑造下一階段的市場競爭格局。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：心臟生物標記診斷試劑盒市場：依生物標記類型分類

  • B型鈉尿肽
  • C反應蛋白
  • 心肌肌鈣蛋白
  • 肌酸激酶-MB
  • 肌紅蛋白

第8章：心臟生物標記診斷試劑盒市場：依適應症分類

  • 心絞痛
  • 心臟衰竭
  • 心肌梗塞

第9章：心臟生物標記診斷試劑盒市場：依檢測類型分類

  • 體外試驗
  • 體內試驗

第10章：心臟生物標記診斷試劑盒市場：按購買方式分類

  • 直接購買
  • 第三方供應商

第11章：心臟生物標記診斷試劑盒市場：按應用領域分類

  • 實驗室檢測
    • 中央檢查
    • 就地檢驗
  • 研究用途

第12章：心臟生物標記診斷試劑盒市場：依最終用戶分類

  • 學術和研究機構
  • 診斷實驗室
  • 醫院和診所

第13章：心臟生物標記診斷試劑盒市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：心臟生物標記診斷試劑盒市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：心臟生物標記診斷試劑盒市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • Atlas Medical GmbH
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Creative Diagnostics
  • Eurolyser Diagnostica GmbH
  • F. Hoffmann-La Roche Ltd.
  • Fujirebio Diagnostics, Inc.
  • GenWay BIoTech, Inc.
  • Guangzhou Wondfo BIoTech Co., Ltd.
  • J.Mitra & Co. Pvt. Ltd.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medtronic Inc.
  • Meridian Bioscience, Inc.
  • MP Biomedicals, LLC
  • Radiometer Medical ApS
  • Randox Laboratories Ltd.
  • Siemens Healthcare GmbH
  • Singulex, Inc.
  • SSI Diagnostica A/S Group
  • Thermo Fisher Scientific, Inc.
  • Tosoh Corporation
  • Trivitron Healthcare
  • Tulip Diagnostics（P）Ltd
Product Code: MRR-433AB1DC288A

The Cardiac Biomarker Diagnostic Kits Market is projected to grow by USD 5.71 billion at a CAGR of 7.47% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.45 billion
Estimated Year [2026] USD 3.69 billion
Forecast Year [2032] USD 5.71 billion
CAGR (%) 7.47%

Cardiac biomarker diagnostic kits are central to modern cardiovascular care because they help clinicians rapidly detect myocardial injury, triage chest pain, monitor heart failure, and support time-sensitive treatment decisions. High-sensitivity cardiac troponin I and T assays remain the clinical cornerstone for suspected acute myocardial infarction, while BNP and NT-proBNP support heart failure assessment, and markers such as CK-MB, myoglobin, D-dimer, and emerging inflammatory or ischemic biomarkers expand the diagnostic context.

The market is being shaped by a persistent global disease burden. The World Health Organization estimates that cardiovascular diseases caused 17.9 million deaths in 2019, representing 32% of global deaths, with heart attacks and strokes accounting for most of these fatalities. This clinical reality sustains demand for accurate, fast, and scalable cardiac biomarker testing across emergency departments, central laboratories, ambulatory settings, and point-of-care environments.

For manufacturers, distributors, laboratories, and health systems, the strategic opportunity lies in delivering cardiac biomarker diagnostic kits that combine analytical sensitivity, workflow efficiency, regulatory compliance, and reliable access. As clinical guidelines continue to emphasize rapid rule-in and rule-out pathways, the competitive advantage increasingly belongs to providers that can align assay performance with operational speed and evidence-based patient management.

Transformative Shifts in the Cardiac Biomarker Testing Landscape

The cardiac biomarker diagnostic kits landscape is moving from single-analyte, laboratory-dependent testing toward integrated diagnostic pathways that combine high-sensitivity assays, point-of-care platforms, multiplex panels, and digital decision support. Emergency departments are adopting accelerated diagnostic protocols that use serial high-sensitivity troponin measurements to reduce time to diagnosis, improve patient flow, and limit unnecessary admissions when clinically appropriate.

Regulatory and reimbursement pressures are also reshaping the market. The European Union In Vitro Diagnostic Regulation has raised expectations for clinical evidence, post-market surveillance, and transparency, while the United States continues to emphasize assay clearance, quality systems, and laboratory performance standards. At the same time, payers and health systems are prioritizing tests that demonstrate measurable value through faster triage, fewer repeat visits, improved outcomes, and lower total cost of care.

Another major shift is decentralization. Hospitals, urgent care networks, and rural providers are seeking reliable point-of-care cardiac testing to close diagnostic gaps where central laboratory turnaround times are impractical. This trend is increasing demand for compact analyzers, cartridge-based kits, connectivity-enabled readers, and quality-control systems that can perform consistently outside traditional laboratory settings.

Cumulative Impact of Artificial Intelligence on Cardiac Biomarker Diagnostics

Artificial intelligence is creating a cumulative impact across the cardiac biomarker diagnostic kits value chain, from assay development and manufacturing quality control to clinical interpretation and hospital workflow optimization. AI-enabled analytics can help identify biomarker patterns, combine troponin results with ECG findings and patient history, and support risk stratification models for patients presenting with chest pain or suspected heart failure.

In clinical operations, AI can reduce friction by prioritizing critical results, predicting testing demand, supporting inventory planning, and integrating biomarker data into electronic health records. When paired with high-sensitivity troponin algorithms, AI-based clinical decision support may help standardize care pathways and reduce variation across emergency departments, provided that outputs are transparent, validated, and monitored for safety.

The most credible AI opportunities will be those grounded in prospective validation, representative datasets, cybersecurity safeguards, and regulatory alignment. Industry leaders should treat AI not as a replacement for clinical judgment, but as a decision-support layer that enhances diagnostic consistency, improves turnaround management, and enables more personalized cardiovascular care.

Key Regional Insights Across Global Cardiac Biomarker Markets

North America remains a leading market for cardiac biomarker diagnostic kits, supported by high emergency department utilization, established laboratory infrastructure, advanced reimbursement systems, and strong adoption of high-sensitivity troponin assays. In the United States and Canada, demand is reinforced by the continuing burden of coronary artery disease and heart failure, as well as by health system goals to improve chest pain triage and reduce avoidable admissions.

Europe is characterized by guideline-driven cardiovascular care, mature diagnostic networks, and a strong regulatory pivot under the EU In Vitro Diagnostic Regulation. Countries across Western Europe are emphasizing analytical quality, clinical evidence, and post-market performance, which benefits suppliers with well-documented high-sensitivity assays and scalable compliance capabilities.

Asia-Pacific is the fastest-evolving opportunity zone, driven by large patient populations, expanding hospital capacity, rising health insurance coverage, and increasing adoption of point-of-care diagnostics. China, India, Japan, South Korea, Australia, and ASEAN markets are advancing at different speeds, but all show rising demand for faster cardiac testing across urban hospitals and underserved regions.

Latin America is expanding through a mix of public hospital modernization and private diagnostic investment, with Brazil and Mexico serving as influential demand centers. The Middle East is benefiting from government-backed healthcare infrastructure projects, particularly in GCC countries, where digital health and specialty cardiac care are policy priorities. Africa presents long-term potential as cardiovascular disease recognition improves, noncommunicable disease programs expand, and decentralized cardiac biomarker testing becomes more important for access-constrained settings.

Key Group Insights for Strategic Market Positioning

ASEAN markets are gaining relevance as governments expand hospital networks, invest in universal health coverage initiatives, and seek cost-effective point-of-care cardiac testing for both urban and secondary-care settings. Demand is strongest where emergency care capacity is improving and private diagnostic chains are scaling access to high-sensitivity troponin and heart failure biomarker testing.

The GCC is moving quickly because healthcare transformation programs in Saudi Arabia, the United Arab Emirates, Qatar, and neighboring markets are prioritizing advanced hospital infrastructure, digital health, and specialty care. These investments support premium cardiac biomarker diagnostic kits, connected analyzers, and integrated laboratory systems aligned with emergency medicine and cardiovascular care pathways.

The European Union is becoming more evidence-intensive under IVDR, favoring organizations that can support clinical performance claims, traceability, post-market surveillance, and notified body review. BRICS economies are important for volume growth, local manufacturing, and price-sensitive procurement, with China, India, and Brazil especially relevant to scale. G7 markets continue to set the pace for innovation, guideline adoption, and reimbursement scrutiny, while NATO countries are increasingly attentive to supply chain resilience for critical diagnostics used in emergency, public health, and military healthcare systems.

Key Country Insights in Cardiac Biomarker Diagnostic Kits

The United States is the most commercially influential country for cardiac biomarker diagnostic kits because of its large hospital network, high cardiovascular disease burden, FDA-regulated diagnostics pathway, and strong demand for rapid emergency department triage. Canada shows steady demand through provincial health systems, quality-focused procurement, and growing use of high-sensitivity troponin protocols, while Mexico is expanding access through public-private healthcare investment and rising diagnostic modernization.

In Latin America, Brazil is the key growth anchor due to its large population, public health system scale, and expanding private laboratory sector. In Europe, the United Kingdom, Germany, France, Italy, and Spain are mature diagnostic markets where guideline adherence, centralized laboratory networks, and IVDR-related compliance shape procurement decisions. Russia remains a distinct market influenced by localization, public procurement priorities, and variable access across regions.

Asia-Pacific country dynamics are diverse. China is scaling cardiac testing through hospital expansion, domestic manufacturing, and centralized procurement reforms. India is driven by a large cardiovascular patient base, rapid private diagnostics growth, and the need for affordable point-of-care options. Japan emphasizes quality, aging-population care, and advanced laboratory workflows, while South Korea combines strong hospital technology adoption with domestic diagnostics capability. Australia demonstrates stable demand through guideline-based care, high laboratory standards, and broad access to cardiac emergency services.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize high-sensitivity troponin, NT-proBNP, and scalable point-of-care platforms that meet real clinical workflow needs. Product strategies should balance premium central laboratory assays with decentralized testing formats that can serve emergency departments, urgent care clinics, ambulances, rural hospitals, and outpatient heart failure programs.

Companies should invest in evidence generation, including clinical performance studies, health economic analyses, and real-world workflow data. Demonstrating reduced time to diagnosis, improved triage accuracy, and measurable operational savings will be increasingly important for winning hospital tenders and payer support.

Leaders should also strengthen supply chain resilience, local regulatory expertise, and digital interoperability. Partnerships with hospital networks, laboratory information system vendors, AI developers, and regional distributors can accelerate adoption. In regulated markets, proactive compliance with FDA, IVDR, and local quality requirements should be treated as a growth enabler rather than a back-office obligation.

Research Methodology

This executive summary is based on a structured research approach that combines verified secondary sources, regulatory review, clinical guideline analysis, and market triangulation. Core reference points include data from the World Health Organization, national health agencies, regulatory bodies such as the FDA and European Commission, and cardiovascular guidance from recognized professional societies.

The methodology evaluates demand drivers across disease burden, hospital workflow, reimbursement, diagnostic technology adoption, and regional healthcare investment. Market interpretation is strengthened by reviewing assay categories, point-of-care adoption patterns, procurement behavior, and regulatory changes affecting in vitro diagnostics.

Insights are triangulated to avoid reliance on a single indicator. Qualitative inputs from clinical practice trends, laboratory operations, and supplier strategies are aligned with quantitative evidence such as cardiovascular mortality data, healthcare infrastructure indicators, and regulatory timelines. The result is an evidence-led perspective designed for strategic planning, SEO-driven market education, and executive decision-making.

Conclusion

The cardiac biomarker diagnostic kits market is positioned for sustained strategic importance as cardiovascular disease remains the leading global cause of mortality and health systems seek faster, more reliable diagnostic pathways. High-sensitivity troponin testing, heart failure biomarkers, point-of-care formats, and digital integration are defining the next phase of market competition.

Growth will be strongest for organizations that can combine analytical excellence with workflow value, regulatory readiness, AI-enabled decision support, and dependable supply. As testing moves closer to the patient and clinical pathways become more data-driven, cardiac biomarker diagnostic kits will continue to play a critical role in improving cardiovascular outcomes and healthcare efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cardiac Biomarker Diagnostic Kits Market, by Biomarker Type

  • 7.1. B-Type Natriuretic Peptide
  • 7.2. C-Reactive Protein
  • 7.3. Cardiac Troponin
  • 7.4. Creatine Kinase-MB
  • 7.5. Myoglobin

8. Cardiac Biomarker Diagnostic Kits Market, by Indication

  • 8.1. Angina Pectoris
  • 8.2. Heart Failure
  • 8.3. Myocardial Infarction

9. Cardiac Biomarker Diagnostic Kits Market, by Testing Type

  • 9.1. In Vitro Testing
  • 9.2. In Vivo Testing

10. Cardiac Biomarker Diagnostic Kits Market, by Purchasing Mode

  • 10.1. Direct Purchasing
  • 10.2. Third-Party Suppliers

11. Cardiac Biomarker Diagnostic Kits Market, by Application

  • 11.1. Laboratory Testing
    • 11.1.1. Central Laboratory Testing
    • 11.1.2. Point-of-Care Testing
  • 11.2. Research Applications

12. Cardiac Biomarker Diagnostic Kits Market, by End User

  • 12.1. Academic & Research Institutions
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals & Clinics

13. Cardiac Biomarker Diagnostic Kits Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Cardiac Biomarker Diagnostic Kits Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cardiac Biomarker Diagnostic Kits Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. Atlas Medical GmbH
  • 17.3. Beckman Coulter, Inc.
  • 17.4. Bio-Rad Laboratories, Inc.
  • 17.5. bioMerieux SA
  • 17.6. Creative Diagnostics
  • 17.7. Eurolyser Diagnostica GmbH
  • 17.8. F. Hoffmann-La Roche Ltd.
  • 17.9. Fujirebio Diagnostics, Inc.
  • 17.10. GenWay Biotech, Inc.
  • 17.11. Guangzhou Wondfo Biotech Co., Ltd.
  • 17.12. J.Mitra & Co. Pvt. Ltd.
  • 17.13. Lepu Medical Technology (Beijing) Co., Ltd.
  • 17.14. Medtronic Inc.
  • 17.15. Meridian Bioscience, Inc.
  • 17.16. MP Biomedicals, LLC
  • 17.17. Radiometer Medical ApS
  • 17.18. Randox Laboratories Ltd.
  • 17.19. Siemens Healthcare GmbH
  • 17.20. Singulex, Inc.
  • 17.21. SSI Diagnostica A/S Group
  • 17.22. Thermo Fisher Scientific, Inc.
  • 17.23. Tosoh Corporation
  • 17.24. Trivitron Healthcare
  • 17.25. Tulip Diagnostics (P) Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL B-TYPE NATRIURETIC PEPTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL B-TYPE NATRIURETIC PEPTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL B-TYPE NATRIURETIC PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL C-REACTIVE PROTEIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL C-REACTIVE PROTEIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL C-REACTIVE PROTEIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC TROPONIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC TROPONIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC TROPONIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CREATINE KINASE-MB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CREATINE KINASE-MB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CREATINE KINASE-MB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MYOGLOBIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MYOGLOBIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MYOGLOBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANGINA PECTORIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANGINA PECTORIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANGINA PECTORIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEART FAILURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEART FAILURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MYOCARDIAL INFARCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MYOCARDIAL INFARCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MYOCARDIAL INFARCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IN VITRO TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IN VITRO TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN VITRO TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IN VIVO TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN VIVO TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IN VIVO TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIRECT PURCHASING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIRECT PURCHASING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIRECT PURCHASING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL THIRD-PARTY SUPPLIERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL THIRD-PARTY SUPPLIERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL THIRD-PARTY SUPPLIERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LABORATORY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LABORATORY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LABORATORY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CENTRAL LABORATORY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CENTRAL LABORATORY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CENTRAL LABORATORY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POINT-OF-CARE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POINT-OF-CARE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POINT-OF-CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. GCC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. GCC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. GCC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. GCC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. GCC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 128. GCC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. GCC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 130. GCC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. G7 CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. G7 CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. G7 CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. G7 CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. G7 CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 152. G7 CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. G7 CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 154. G7 CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. NATO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NATO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NATO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. NATO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 162. NATO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 175. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 177. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 179. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 185. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 187. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 193. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 195. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED KINGDOM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED KINGDOM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED KINGDOM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED KINGDOM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED KINGDOM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED KINGDOM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED KINGDOM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED KINGDOM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 209. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 211. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 217. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 219. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 225. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 227. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 231. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 233. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 235. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 241. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 243. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 257. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 259. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 263. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 265. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 267. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 271. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 273. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 275. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 279. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2032 (USD MILLION)
  • TABLE 281. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2032 (USD MILLION)
  • TABLE 283. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)